Compare · CNCR vs DWSH

CNCR vs DWSH

Side-by-side comparison of Loncar Cancer Immunotherapy ETF (CNCR) and AdvisorShares Dorsey Wright Short ETF (DWSH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CNCR and DWSH operate in n/a (n/a), so they compete in similar markets.
MetricCNCRDWSH
Company
Loncar Cancer Immunotherapy ETF
AdvisorShares Dorsey Wright Short ETF
Price
-
-
Market cap
-
-
1M return
-
-
1Y return
-
-
Sector
n/a
n/a
Industry
n/a
n/a
Exchange
NASDAQ
NASDAQ
IPO
n/a
n/a
News (4w)
0
0
Recent ratings
0
0
CNCR

Loncar Cancer Immunotherapy ETF

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

DWSH

AdvisorShares Dorsey Wright Short ETF

The investment seeks capital appreciation through short selling securities. Dorsey, Wright & Associates, LLC (the "Sub-Advisor"), the sub-advisor to the fund, seeks to achieve the fund's investment objective by obtaining short exposure to investment returns of the broad U.S. large-capitalization equity market by engaging in short sales of U.S.-traded equity securities and exchange-traded funds ("ETFs"). Under normal circumstances, it invests at least 80% of its net assets (plus any borrowings for investment purposes) in investments that create or result in short exposure to U.S. equity securities.